Circulating soluble fms-like tyrosine kinase-1 and placental growth factor from 10 to 40 weeks' pregnancy in normotensive women

Journal of Perinatal Medicine

Volumn 45, Issue 7, 2017, Pages 895-901

  Wataganara, Tuangsit ^a   Pratumvinit, Busadee ^a   Lahfahroengron, Piyaporn ^a   Pooliam, Julaporn ^a   Talungchit, Pattarawalai ^a   Leetheeragul, Jarunee ^a   Sukpanichnant, Sathien ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Placental growth factor; preeclampsia screening; serum biomarker; soluble fms like tyrosine kinase 1

Indexed keywords

PLACENTAL GROWTH FACTOR; VASCULOTROPIN RECEPTOR 1; FLT1 PROTEIN, HUMAN;

ADULT; AGE; ARTICLE; BIRTH WEIGHT; BLOOD LEVEL; BODY MASS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; GESTATION PERIOD; HUMAN; INFERTILITY THERAPY; LOW RISK PATIENT; OBSERVATIONAL STUDY; PARITY; PLACENTA WEIGHT; PREECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PREGNANT WOMAN; PRIORITY JOURNAL; SMOKING; THAI (CITIZEN); TOBACCO USE; BLOOD; REFERENCE VALUE; YOUNG ADULT;

ADULT; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; PLACENTA GROWTH FACTOR; PREGNANCY; REFERENCE VALUES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; YOUNG ADULT;

EID: 85031006080     PISSN: 03005577     EISSN: 16193997     Source Type: Journal    
DOI: 10.1515/jpm-2017-0093     Document Type: Article

References (21)

1. Poon LC, Kametas NA, Chelemen T, Leal A, Nicolaides KH. Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach. J Hum Hypertens. 2010; 24: 104-10
2. Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennstrom M, et al. Predictive Value of the sFlt-1: PlGF Ratio in Women with Suspected Preeclampsia. N Engl J Med. 2016; 374: 13-22
3. Cuckle HS. Screening for pre-eclampsia -lessons from aneuploidy screening. Placenta 2011; 32(Suppl.): S42-8
4. LeFevre ML, Force USPST. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014; 161: 819-26
5. Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol. 2010; 202: 161 e1-11
6. Ohkuchi A, Hirashima C, Suzuki H, Takahashi K, Yoshida M, Matsubara S, et al. Evaluation of a new and automated electrochemiluminescence immunoassay for plasma sFlt-1 and PlGF levels in women with preeclampsia. Hypertens Res. 2010; 33: 422-7
7. Tsiakkas A, Duvdevani N, Wright A, Wright D, Nicolaides KH. Serum soluble fms-like tyrosine kinase-1 in the three trimesters of pregnancy: effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol. 2015; 45: 584-90
8. Tsiakkas A, Duvdevani N, Wright A, Wright D, Nicolaides KH. Serum placental growth factor in the three trimesters of pregnancy: effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol. 2015; 45: 591-8
9. O'Gorman N, Wright D, Syngelaki A, Akolekar R, Wright A, Poon LC, et al. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation. Am J Obstet Gynecol. 2016; 214: 103e1-12
10. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004; 350: 672-83
11. National Collaborating Centre for Womens and Childrens Health (UK). Hypertension in Pregnancy: The Management of Hypertensive Disorders During Pregnancy. London, UK: RCOG Press; 2010
12. Palmer KR, Tong S, Kaituu-Lino TJ. Placental-specific sFLT-1: role in pre-eclamptic pathophysiology and its translational possibilities for clinical prediction and diagnosis. Mol Hum Reprod. 2017; 23: 69-78
13. Manthati S, Pratumvinit B, Hanyongyuth R, Udompunthurak S, Phaophan A, Wataganara T. Circulating free soluble fms-like tyrosine kinase-1 during late first trimester in relation with placental volume as a surrogate for trophoblastic production: A physiology study in low-risk cohort. J Matern Fetal Neonatal Med. 2017; 30: 1976-83
14. Holston AM, Qian C, Yu KF, Epstein FH, Karumanchi SA, Levine RJ. Circulating angiogenic factors in gestational proteinuria without hypertension. Am J Obstet Gynecol. 2009; 200: 392e1-10
15. Villa PM, Hamalainen E, Maki A, Raikkonen K, Pesonen AK, Taipale P, et al. Vasoactive agents for the prediction of earlyand late-onset preeclampsia in a high-risk cohort. BMC Pregnancy Childbirth. 2013; 13: 110
16. Alahakoon TI, Zhang W, Trudinger BJ, Lee V. Discordant clinical presentations of preeclampsia and intrauterine fetal growth restriction with similar pro and anti-angiogenic profiles. J Matern Fetal Neonatal Med. 2014; 27: 1854-9
17. Triunfo S, Crispi F, Gratacos E, Figueras F. Prediction of delivery of small for gestational age neonates and adverse perinatal outcomes by feto-placental Doppler at 37 weeks gestation. Ultrasound Obstet Gynecol. 2017; 49: 364-71
18. Sibai BM, Abdella TN, Anderson GD, McCubbin JH. Plasma volume determination in pregnancies complicated by chronic hypertension and intrauterine fetal demise. Obstet Gynecol. 1982; 60: 174-8
19. Meiri H, Huppertz B, Cetin I. Development of early non-invasive markers and means for the diagnosis and progression monitoring of preeclampsia and tailoring putative therapies (project pregenesys 037244). Placenta 2011; 32(Suppl.): S1-3
20. Sibiude J, Guibourdenche J, Dionne MD, Le Ray C, Anselem O, Serreau R, et al. Placental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction. PLoS One 2012; 7: e50208
21. Khalil A, Maiz N, Garcia-Mandujano R, Penco JM, Nicolaides KH. Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia. Ultrasound Obstet Gynecol. 2016; 47: 324-31